Immune cell treatment for H3K27M-mutant brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new immune cell therapy for people with a specific type of brain tumor (diffuse midline glioma or diffuse intrinsic pontine glioma) that has returned or not responded to standard treatment. The treatment uses specially engineered immune cells to target a protein called H3K27M, which is found on these tumors. This study aims to see if this therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be between 2 and 70 years old.
- You must have a confirmed H3K27M-mutant diffuse midline glioma or diffuse intrinsic pontine glioma that has come back or not responded to standard treatment.
- You must have adequate organ function (kidney, liver, heart, and blood counts).
- You must not be on high-dose steroids (dexamethasone 4 mg/day or less).
- You must be willing to follow study instructions and use birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (a dendritic cell vaccine) that may help your body fight the brain tumor. It is meant for people with DIPG or glioblastoma who have already tried standard treatments but still have tumors.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This trial tests an experimental immune cell therapy for a type of brain tumor called malignant meningioma that has come back after standard treatment. The goal is to see if these special immune cells can help control the tumor.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Hear when a new Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.